Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Cost of Revenue: 2021-2024

Historic Cost of Revenue for Tarsus Pharmaceuticals (TARS) over the last 4 years, with Dec 2024 value amounting to $12.8 million.

  • Tarsus Pharmaceuticals' Cost of Revenue rose 156.29% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.7 million, marking a year-over-year increase of 170.77%. This contributed to the annual value of $12.8 million for FY2024, which is 705.15% up from last year.
  • Per Tarsus Pharmaceuticals' latest filing, its Cost of Revenue stood at $12.8 million for FY2024, which was up 705.15% from $1.6 million recorded in FY2023.
  • Tarsus Pharmaceuticals' Cost of Revenue's 5-year high stood at $12.8 million during FY2024, with a 5-year trough of $955,000 in FY2022.
  • Its 3-year average for Cost of Revenue is $5.1 million, with a median of $1.6 million in 2023.
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Cost of Revenue plummeted by 53.98% in 2022, and later spiked by 705.15% in 2024.
  • Tarsus Pharmaceuticals' Cost of Revenue (Yearly) stood at $2.1 million in 2021, then crashed by 53.98% to $955,000 in 2022, then spiked by 66.81% to $1.6 million in 2023, then spiked by 705.15% to $12.8 million in 2024.